Skip to main content

Table 2 Patient demographics and baseline characteristics

From: Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy

 

Achieved CR

Did not achieve CR

Characteristic

Glasdegib + LDAC

N = 15

LDAC alone

N = 1

Glasdegib + LDAC

N = 63

LDAC alone

N = 37

Age (years), n (%)

 45–64

0

0

1 (1.6)

1 (2.7)

 ≥ 65

15 (100)

1 (100)

62 (98.4)

36 (97.3)

 Median (range)

74 (65–87)

78 (78–78)

77 (64–92)

76 (58–83)

Sex, n (%)

 Female

5 (33.3)

1 (100)

14 (22.2)

14 (37.8)

 Male

10 (66.7)

0

49 (77.8)

23 (62.2)

ECOG PS, n (%)

 0

0

1 (100)

10 (15.9)

2 (5.4)

 1

5 (33.3)

0

21 (33.3)

17 (45.9)

 2

10 (66.7)

0

31 (49.2)

18 (48.6)

 Not reported

0

0

1 (1.6)

0

Cytogenetic risk, n (%)

 Good/intermediate risk

12 (80.0)

0

41 (65.1)

22 (59.5)

 Poor risk

3 (20.0)

1 (100)

22 (34.9)

15 (40.5)

ELN risk stratification, n (%)

 Favorable

1 (6.7)

0

4 (6.3)

3 (8.1)

 Intermediate I

8 (53.3)

0

19 (30.2)

11 (29.7)

 Intermediate II

3 (20.0)

0

18 (28.6)

8 (21.6)

 Adverse

3 (20.0)

1 (100)

22 (34.9)

15 (40.5)

Disease history, n (%)

 De novo

7 (46.7)

1 (100)

31 (49.2)

17 (45.9)

 Secondary AML

8 (53.3)

0

32 (50.8)

20 (54.1)

Mutations, n (%)*

FLT3

0

0

5 (7.9)

0

IDH1 or IDH2

4 (26.7)

0

15 (23.8)

6 (16.2)

NPM1

1 (6.7)

0

4 (6.3)

1 (2.7)

 Unknown

4 (26.7)

0

16 (25.4)

13 (35.1)

  1. AML acute myeloid leukemia, CR complete remission, ECOG PS Eastern Cooperative Oncology Group performance status, ELN European LeukemiaNet, LDAC low-dose cytarabine
  2. *Baseline gene mutations were determined in 58/78 patients receiving glasdegib + LDAC (CR, n = 11; no CR, n = 47) and 25/38 patients receiving LDAC alone (CR, n = 1; no CR, n = 24)
  3. Includes only FLT3 point mutations